Morning Briefing: Is the first cancer vaccine coming as early as next year?
Moderna and US partner Merck are presenting study data for a new cancer vaccine - and not only fueling investors' imaginations. With mRNA, tumors could be prevented with a vaccination.
Moderna and Merck & Co. have reported promising results from a study on a new skin cancer treatment. The personalized cancer vaccine, which uses mRNA technology, reduced the risk of certain malignant skin tumors recurring or spreading to other parts of the body. If confirmed, this could be a breakthrough in the fight against cancer.
Moderna's CEO Stéphane Bancel believes the technology could lead to a lucrative new era, with the global mRNA therapeutics market expected to grow to around $21.5 billion by 2030. Moderna's stock rose 17.6 percent following the announcement.
Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
